Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Dollar Gains on Safe-Haven Demand as Iran Tensions and Inflation Data Loom 
Trump Administration Releases New UFO Files and Apollo Mission Records 
Gold Prices Slip as Strong Dollar and Rising Oil Weigh on Market Sentiment 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Nike Tariff Refund Lawsuit Sparks Consumer Backlash Over Price Increases 
Moderna to Pay Up to $2.25B to Settle LNP Patent Dispute Over COVID-19 Vaccine Technology 
U.S. Officials Express Optimism Over New CDC Director Selection Amid Vaccine Policy Turmoil 
Is dark chocolate healthier than milk chocolate? 2 dietitians explain 
Asian Currencies Slide as Iran Tensions Boost Dollar and Oil Prices 
OpenAI-Microsoft Deal Sets $38 Billion Revenue-Sharing Cap Ahead of Potential IPO 
Blue Origin’s New Glenn Achieves Breakthrough Success With First NASA Mission 
Judge Delays SEC Settlement With Elon Musk Over Twitter Stock Disclosure Case 
Tabletop particle accelerator could transform medicine and materials science 
Goldman Sachs Delays Fed Rate Cut Forecast to 2026 Amid Rising Inflation Concerns 
Trump Says Iran Ceasefire Near Collapse as Oil Prices Surge 
South Korea will invest 274.6 billion won in the bio-industry this year for 252 new R&D projects in the four fields of biopharmaceuticals, healthcare, biomaterials, and medical equipment in 2023.
According to South Korea’s Ministry of Trade, Industry and Energy, 94.8 billion won would be allocated to developing new medicines, microbiome analysis, and other biomanufacturing process technology.
Around 69.5 billion won will support the development of advanced medical appliances, and 30 billion won will be for developing state-of-the-art biomaterials.
The ministry added that beefing up support for biomaterials and other new fields of the sector would promote innovation.
